Latest News

FDA advisors recommend lofexidine for opioid withdrawal


 

REPORTING FROM AN FDA ADVISORY COMMITTEE MEETING


The Prescription Drug User Fee Act (PDUFA) for lofexidine is May 26; FDA actions on new drug applications often occur at near the PDUFA date.


The FDA is not obligated to follow the recommendations of its advisory committees.

Pages

Recommended Reading

Opioid deaths in the ED increase nationally
MDedge Internal Medicine
Opioid prescriptions got shorter in 2017
MDedge Internal Medicine
Alcohol dependence may accelerate aging, frontal cortical deficits
MDedge Internal Medicine
Interventions urged to stop rising NAS, stem Medicaid costs
MDedge Internal Medicine
Congress tackles the opioid epidemic. But how much will it help?
MDedge Internal Medicine
FDA wants data on role of flavored tobacco products in youth initiation
MDedge Internal Medicine
MDedge Daily News: Stem cells may reverse premature menopause
MDedge Internal Medicine
Is kratom the answer to the opioid crisis?
MDedge Internal Medicine
U.S. adults consumed 17.5 billion total binge drinks in 2015
MDedge Internal Medicine
MDedge Daily News: Is kratom the answer to the opioid crisis?
MDedge Internal Medicine